RxDoctor Payments Data

Theresa Runyon, NP

Registered Nurse · Walnut Creek, CANPI 1316948235

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 24 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Amgen at 29.6% of the total. Among registered nurse clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$1,027in general payments, 2019–2025

Across 24 payments — averaging $42.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$304
  • Nxstage Medical, Inc.$192
  • Ardelyx, Inc.$192
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$123
  • Fresenius USA Marketing, Inc.$84
  • Vifor Pharma, Inc.$67
  • plus $65 from 3 others

What the payments were for

  • Food & beverage$1,027100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,027 in reported general payments places this provider in the 90th percentile of 533 registered nurse providers in California.

See all registered nurse providers in California

Medicare billing

Part B allowed, 2024
$22,918
Medicare patients
49
Services billed
138

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide18$48,485
Sevelamer Carbonate39$5,265
Calcium Acetate22$2,709
Bumetanide15$458
Lidocaine-PrilocaineLidocaine/Prilocaine14$324
Amlodipine Besylate12$58

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$84$48,48518 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 533 registered nurse providers in California.

Other registered nurse in Walnut Creek

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →